Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Drug Safety Labeling Changes
Intermittent self-catheterisation in MS.
Alemtuzumab for the Treatment of Multiple Sclerosis
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Antigen-specific tolerance by autologous myelin Peptide-coupled cells: a phase 1 trial in multiple sclerosis.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
American Academy of Neurology Annual Meeting
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
One calcitriol dose transiently increases Helios(+)FoxP3(+) T cells and ameliorates autoimmune demyelinating disease.
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Receptos reports third quarter 2013 financial results
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
EMD Serono
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Ustekinumab success in refractory Crohn’s disease
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.

Pages